

1 **Visceral Leishmaniasis-HIV coinfection as a predictor of increased *leishmania* transmission at the**  
2 **village level in Bihar, India.**  
3

4 **Authors: Kristien Cloots, MD\*<sup>1∞</sup>, Pia Marino, MD\*<sup>1,2</sup>, Sakib Burza, PhD<sup>3</sup>, Naresh Gill,**  
5 **MD<sup>4</sup>, Marleen Boelaert, PhD<sup>1</sup>, Epcó Hasker, PhD<sup>1</sup>**  
6

7 <sup>1</sup> Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

8 <sup>2</sup> Erasmus Mundus Joint Master Degree Infectious Diseases & One Health Programme

9 <sup>3</sup> Médecins Sans Frontières, New Delhi, India

10 <sup>4</sup> National Vector Borne Disease Control Programme, India

11 ∞Corresponding author

12 \*These authors contributed equally to this work  
13  
14  
15

16 **ABSTRACT**

17 **Background :** Visceral leishmaniasis (VL) is on the verge of being eliminated as a public health  
18 problem in the Indian subcontinent. Although Post-kala-azar dermal leishmaniasis (PKDL) is  
19 recognized as an important reservoir of transmission, we hypothesized that patients with VL co-  
20 infected with Human Immunodeficiency Virus (HIV) may also be important reservoirs of  
21 sustained leishmania transmission. We therefore investigated to what extent cases of PKDL or  
22 VL-HIV are associated with VL incidence at the village level in Bihar, India.

23 **Methods :** VL, VL-HIV, and PKDL case data from six districts within the highly VL-endemic  
24 state of Bihar, India were collected through the Kala-Azar Management Information System for  
25 the years 2014 – 2019. Multivariate analysis was done using negative binomial regression  
26 controlling for year as a fixed effect and block (subdistrict) as a random effect.  
27

28 **Findings :** Presence of VL-HIV and PKDL cases were both associated with a more than twofold  
29 increase in VL incidence at village level, with Incidence Rate Ratios (IRR) of 2.16 (95% CI 1.81  
30 – 2.58) and 2.37 (95% CI 2.01 – 2.81) for VL-HIV and PKDL cases respectively. A sensitivity  
31 analysis showed the strength of the association to be similar in each of the six included  
32 subdistricts.  
33

34 **Conclusions :** These findings indicate the importance of VL-HIV patients as infectious  
35 reservoirs, and suggest that they represent a threat equivalent to PKDL patients towards the VL  
36 elimination initiative on the Indian subcontinent, therefore warranting a similar focus.  
37

## 38 **CONTRIBUTION TO THE FIELD**

39 Visceral leishmaniasis (VL) – also called kala azar on the Indian subcontinent - is a parasitic  
40 disease which is fatal if not treated timely. Since the elimination initiative was launched in 2005  
41 in the Indian subcontinent, the number of cases has come down drastically in this region.  
42 However, with the regional incidence of VL decreasing, understanding the role of potentially  
43 highly infectious subgroups in maintaining refractory Leishmania transmission is becoming  
44 increasingly important. Patients with Post-Kala-Azar Dermal Leishmaniasis (PKDL) are  
45 recognized as an important reservoir of transmission. We hypothesized that VL patients co-  
46 infected with Human Immunodeficiency Virus (HIV) may also be important reservoirs of  
47 sustained leishmania transmission. In this study, we found that the presence of VL-HIV and  
48 PKDL patients are both associated with a twofold increase incidence of VL at village level,  
49 suggesting they are equally important reservoirs for leishmania transmission. Our paper suggests  
50 that VL-HIV patients pose a threat equivalent to PKDL patients towards the VL elimination  
51 initiative and that therefore they should receive a similar focus.

52  
53  
54  
55  
56  
57

58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73

74

75

76

## 77 INTRODUCTION

78 Visceral Leishmaniasis (VL) - also called *kala-azar* (KA) - is a potentially fatal parasitic disease,  
79 caused by *Leishmania donovani* on the Indian subcontinent. Fifteen years after a Memorandum  
80 of Understanding was signed by the governments of India, Nepal and Bangladesh committing to  
81 its elimination as a public health problem, the goal is on the verge of being achieved. However,  
82 with the regional incidence of VL decreasing, understanding the role of potentially highly  
83 infectious subgroups in maintaining refractory *Leishmania* transmission is becoming  
84 increasingly important.

85 Post kala-azar dermal leishmaniasis (PKDL) is an infectious cutaneous sequel that follows VL in  
86 an estimated 5-10% of treated cases in Asia, typically 1-3 years following completion of therapy  
87 [1, 2]. Because patients with PKDL usually do not have any symptoms other than painless skin  
88 lesions, a minority of these patients actively seek medical care, while the condition is often  
89 misdiagnosed as leprosy or vitiligo [1, 3]. Untreated PKDL can remain symptomatic for several  
90 years [4, 5]. Following the near elimination of VL from the Indian subcontinent in the 1970s,  
91 PKDL was suspected to have been the interepidemic reservoir responsible for triggering a new  
92 VL outbreak years after the last VL case had been reported in West Bengal [6]. As such PKDL is  
93 considered a largely hidden but persistent reservoir of infection, and remains a major threat to the  
94 sustainability of the elimination initiative.

95 In Bihar, the most endemic state for VL in India, an estimated 2-7% of VL cases are co-infected  
96 with HIV [7-9], although this is most likely an underestimation of the true burden [10]. Data  
97 from other settings in the Indian subcontinent are limited, in part due to a lack of routine testing  
98 [10]. VL patients co-infected with HIV have been shown to be highly infectious [11]. HIV and  
99 leishmaniasis share an immunopathological pathway that enhances replication of both pathogens  
100 and accelerates the progression of both VL and HIV [12-14]. A concomitant HIV infection  
101 increases the risk of developing active VL by between 100 and 2,320 times [15, 16]. Diagnosing  
102 VL in HIV-co-infected patients also poses a major challenge, as VL symptoms are less typical  
103 and existing diagnostic tools less accurate [17]. In addition, patients with VL-HIV coinfection  
104 experience a lower therapeutic success rate for VL, experience greater drug related toxicity and  
105 relapse more frequently than patients not infected with HIV [12, 18, 19]. With each new episode  
106 of VL becoming increasingly difficult to treat [20], these patients are likely to remain infectious  
107 reservoirs for prolonged periods of time. However, their exact contribution to transmission of VL  
108 has yet to be determined.

109 We hypothesized that with the overall decrease in VL cases reported in the Indian subcontinent,  
110 PKDL and VL-HIV cases act as important reservoirs of *leishmania* transmission. We therefore  
111 investigated to what extent the presence of patients with PKDL or VL-HIV is associated with VL  
112 incidence at the village level in Bihar, India.

## 113 **METHODS**

### 114 *Study site*

115 The state of Bihar is located in northern India and is characterized by a very dense population of  
116 approximately 120 million, of which over a third live below the poverty line [21]. In 2019, Bihar  
117 reported 77% of all VL cases in India [22]. At the same time it carries the second highest  
118 number of new HIV infections in the country, and is one of the seven Indian states where  
119 reported AIDS related deaths continue to rise [23]. Estimates of the proportion of reported VL  
120 patients co-infected with HIV in Bihar state are between 2-7%, although in districts where  
121 reliable HIV screening was present up to 20% of adults diagnosed with VL were HIV positive  
122 [9, 10]. Six districts within Bihar state were selected for this study on the basis of having the  
123 highest VL burden and being geographically contiguous; Darbhanga, Muzaffarpur, Samastipur,  
124 Saran, Siwan, and Vaishali (Figure 1).

### 125 *Data sources*

126 Routinely collected program data – including the date of diagnosis and the village of residence -  
127 on incident VL, PKDL and VL-HIV coinfecting cases between January 2014 and December 2019  
128 were collected for the six selected districts. These data were retrieved through the Kala-azar  
129 Management Information System (KAMIS) – an online reporting tool centralizing case reports  
130 of leishmaniasis from all VL endemic states within India - with permission of the National  
131 Vector Borne Disease Control Program (NVBDCP), India. The national 2011 population census  
132 was used as a basis for the population size per village, and adapted to a 2.5% population growth  
133 per year. A village level spatial GIS dataset for these districts was made available through the  
134 KalaCORE consortium.

### 135 *Data cleaning*

136 The initial database included data on 7,886 patients. Double entries – identified based on date of  
137 diagnosis, sex, age, and place of residence - were removed from the database, as were patients  
138 for whom the village of residence could not be matched with any of the villages available  
139 through the census dataset. VL patients for whom no HIV test result was recorded (n = 2,287)  
140 were assumed to be HIV negative. 2,357 villages with less than 1,000 inhabitants were attributed  
141 to the nearest larger village, using the ‘distance matrix’ module in Quantum Geographical  
142 Information Systems (QGIS). One block (= subdistrict) with no reported cases of VL during the  
143 study period was considered to be non-endemic for leishmaniasis and was therefore excluded  
144 from the analysis. None of the villages (agglomerates) with a population > 50,000 (n = 9)  
145 reported any VL cases; they were therefore excluded from further analysis.

146

## 147 *Statistical analysis*

148 Data analysis was performed with Stata 14 [StataCorp, Texas, USA]. In a first step we assessed  
149 whether VL incidence in a village differed by the presence or absence of VL-HIV or PKDL  
150 cases. For this we calculated the mean VL incidence in villages with and without:

151 a) HIV-VL cases in the same year,

152 b) PKDL cases in the same year,

153 c) HIV-VL cases in the previous year, and

154 d) PKDL cases in the previous year, and compared both values using Kruskal-Wallis test (non-  
155 normal distribution).

156 In a next step, we assessed to what extent presence of VL-HIV or PKDL cases was associated  
157 with VL incidence at village level, by building a multivariate model using negative binomial  
158 regression. The VL-HIV cases themselves were excluded from the outcome variable (VL  
159 incidence). As PKDL can be both cause and effect of VL, we evaluated PKDL in the previous  
160 year as a potential predictor for VL incidence (instead of PKDL in the same year). Year of  
161 reporting and block (= subdistrict) were assessed as potential confounders, block as random  
162 effect and year as fixed effect.

## 163 *Ethical considerations*

164 Ethical clearance for this study was obtained from the Institutional Review Board of the Institute  
165 of Tropical Medicine, Antwerp, Belgium. The retrospective analysis of routinely collected  
166 programme data was supported and approved by the National Vector Borne Disease Control  
167 Programme (NVBDCP), Ministry of Health and Family Welfare, India.

168

## 169 **RESULTS**

### 170 *Descriptive statistics*

171 A total of 7,497 cases were included in the analysis; 6,515 cases of VL, 397 cases of VL-HIV,  
172 and 585 cases of PKDL. 5.7% (397/6,909) of all VL cases were co-infected with HIV at the time  
173 of diagnosis. 37.8% (2,247/5,938) of the included villages reported  $\geq 1$  case of VL during the  
174 study period; while 5.4% (322/5,938) and 7.3% (434/5,938) of the villages reported  $\geq 1$  HIV-VL  
175 case and  $\geq 1$  PKDL case respectively. Exact distribution of VL, VL-HIV and PKDL cases per  
176 year and per district is graphically represented in Figure 2; underlying numbers are available in  
177 S1 Table and S2 Table.

178

## 179 *Comparison of VL incidence at village level*

180 The overall mean annual VL incidence of all villages between 2014-2019 was 0.59/10,000  
181 population per year. The mean annual VL incidence rate was significantly higher in villages with  
182 VL-HIV or PKDL cases present in the same or the previous year (Table 1). Cumulative  
183 incidence per year and per district can be found in S3 Table and S4 Table.

## 184 *Developing the negative binomial model*

185 In the bivariate (unadjusted) analysis, both presence of VL-HIV in the same year and presence of  
186 PKDL in the previous year were found to be strong predictors for VL incidence at the village  
187 level, with Incidence Rate Ratios (IRR) of 4.07 (95% CI 2.94 – 5.63) and 4.63 (95% CI 3.30 –  
188 6.49) respectively. The year of reporting was identified as a confounder.

189 A multivariate model was then built, with VL incidence as outcome, and the presence of VL-  
190 HIV cases in the same year as well as presence of PKDL cases in the previous year as predictors,  
191 while controlling for year as a confounder and using block as a random effect to adjust for  
192 contextual confounding. The model was further explored by adding an interaction term for VL-  
193 HIV(same year)\*PKDL(previous year), but no interaction was found to be present. Our final  
194 model can therefore be summarized as follows: VL incidence ~ VL-HIV (same year) + PKDL  
195 (previous year) + year + block(random effect). In summary, presence of VL-HIV in the same  
196 year and of PKDL in the previous year both remained strong predictors for VL incidence at  
197 village level, with an adjusted IRR of 2.16 (95% CI 1.81 – 2.58) and 2.37 (95% CI 2.01 – 2.81)  
198 respectively. Results of the bivariate (unadjusted) and multivariate (adjusted) negative binomial  
199 regression model can be found in Table 2.

## 200 *Sensitivity analysis*

201 A sensitivity analysis was done fitting the final multivariate negative binomial model for each of  
202 the districts separately. As shown in Figure 3, this consistently showed an increased VL  
203 incidence in the presence of current VL-HIV cases or PKDL cases in the previous year in all  
204 districts, though for PKDL this difference was not significant in one district (underlying numbers  
205 and confidence intervals are detailed in S5 Table).

206

## 207 **DISCUSSION**

208 This study suggests that presence of either VL-HIV or PKDL patients is associated with a greater  
209 than twofold increase in VL incidence at village level (IRR 2.16 and 2.37 for VL-HIV and  
210 PKDL respectively). A similar effect of VL-HIV and PKDL was found in all six districts; though  
211 not statistically significant in all, demonstrating a consistent trend supports causality as an  
212 explanation. Although the case for focus on PKDL identification and treatment is widely  
213 accepted as an important strategy in achieving sustainable elimination [1], these findings indicate  
214 the importance of VL-HIV patients as infectious reservoirs, and that a lack of equivalent focus  
215 on this cohort may represent a similar level of threat to the VL elimination initiative on the  
216 Indian subcontinent.

217

218 This is the first study that attempts to quantify the impact of VL-HIV on population-level  
219 transmission within endemic areas. The main strength of this analysis is that our model takes into  
220 account the chronological hierarchy between VL and PKDL, excluding as a predictor the PKDL  
221 cases which might have developed in a VL case reported earlier in the same year, which would  
222 artificially have increased the association.

223 There are a number of limitations in this study. Routinely collected programme data will likely  
224 be an underestimation of the real disease burden, not only of VL but also of VL-HIV co-  
225 infections and PKDL, the latter two of which are difficult to identify. Despite active case finding  
226 and numerous information, education and communication (IEC) initiatives implemented as part  
227 of the elimination strategy, PKDL patients tend not to seek medical care unless for cosmetic  
228 reasons, as they do not feel unwell. Simultaneously, the recommendation for routine testing for  
229 HIV of all patients diagnosed with VL in India was only made in 2014, and has taken time to be  
230 implemented. Meanwhile, there is no routine screening for VL in patients with HIV living in VL  
231 endemic areas in India, despite national recommendations, primarily because of the lack of tools  
232 to enable this [9].

233 Additionally, in the analysis, VL patients for whom no HIV test result was recorded were  
234 assumed to be HIV negative. Zero reporting of results in health care surveillance systems  
235 remains uncommon, so although this assumption will most likely be correct for most of the  
236 patients, some VL cases may have been incorrectly considered as HIV negative.

237 Both PKDL and VL-HIV patients have been shown to be infectious through xenodiagnosis, a  
238 procedure in which a vector is allowed to feed on a host in order to verify whether or not they get  
239 infected. A recent study from Bangladesh showed that PKDL is only slightly less infectious than  
240 VL, with 57% of PKDL patients infecting at least one sand fly compared to 67% of VL patients  
241 [24]. Through the same technique, patients with VL-HIV have also been shown to be highly  
242 infectious, with even asymptomatic cases infecting vectors, albeit with a different *leishmania*  
243 species and in a different context [25, 26]. However no such study on VL-HIV patients has been  
244 published on the Indian subcontinent.

245 Evidence on the relative contributions of PKDL and VL-HIV to the transmission of *leishmania* is  
246 still evolving. While a 2016 longitudinal study from India reported no evidence of increased  
247 transmission in households with PKDL patients over an 18-month follow-up period compared to  
248 control households [27], mathematical modeling suggests an increasingly important role for  
249 PKDL in the years to come [28]. VL-HIV cases on the other hand are traditionally not included  
250 in mathematical models, and the results of this study suggest that this be an important area of  
251 consideration for modelers. While the necessity to include PKDL in the elimination efforts has  
252 by now been widely accepted, this study suggests that the VL-HIV reservoir warrants an  
253 equivalent focus in operational strategies if sustainable elimination is to be achieved. The results  
254 of this study would *a-priori* also support the recent recommendation of the use of LLINs in  
255 patients diagnosed with PKDL and VL-HIV from the 7<sup>th</sup> WHO-SEARO Regional Technical  
256 Advisory Group for Kala Azar.

257 There remain major gaps in the diagnosis and management of both PKDL and VL-HIV in the  
258 Indian subcontinent. PKDL remains for the most part a clinical diagnosis, with the potential for

259 mis-identification and missed treatment remaining a major issue. Meanwhile, treatment of PKDL  
260 remains challenging, with a 12-week course of oral Miltefosine, a teratogenic oral drug with poor  
261 compliance and significant side effects, being the only currently recommended treatment [29].  
262 Meanwhile, there remains little evidence on the sensitivity or specificity of existing non-invasive  
263 tests for VL in HIV patients, and considering the case definition of VL remains the same for co-  
264 infected and immunocompetent patients, it is likely that a substantial number of co-infected  
265 patients are missed. In addition, management of co-infected patients remains fraught with  
266 challenges [10, 30]. New tools and strategies are urgently required to improve case detection and  
267 management of both entities to reduce their infectious potential. This will both improve the  
268 chances, and indeed capitalize on the substantial investment, of sustainable elimination in the  
269 subcontinent.

### 270 *Conflict of interest*

271 The authors declare that the research was conducted in the absence of any commercial or  
272 financial relationships that could be construed as a potential conflict of interest.

### 273 *Author contributions*

274 EH, SB, PM, and KC contributed to the conception and design of the study. Data curation was  
275 performed by NG, PM and EH. Formal analysis was performed by PM and KC and validated by  
276 SB and EH. Writing of the original draft manuscript was performed by PM and KC. All authors  
277 contributed to manuscript revision, read, and approved the submitted version.

### 278 *Data availability*

279 Data cannot be shared publicly by the researchers as they are property of the National Vector  
280 Borne Disease Control Programme (NVBDCP) of India. They are available to others on  
281 condition of request and approval of the NVBDCP (contact via [nareshgill.nvbdcpl@yahoo.com](mailto:nareshgill.nvbdcpl@yahoo.com)).

282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298



299 **FIGURES AND TABLES**

300 *Figure captions*

301 **Figure 1** : Geographical location of the six study districts within Bihar state, India.

302 **Figure 2** : Number of VL, VL-HIV, and PKDL cases reported per year and per district.

303 **Figure 3** : Tornado chart graphically representing the results of the sensitivity analysis of the  
 304 final model for the different districts. On the horizontal axis, the adjusted Incidence Rate Ratio is  
 305 displayed for VL-HIV in the same year and PKDL in the previous year respectively.

306 *Tables*

307 **Table 1** : Mean VL incidence per 10,000 population per year, comparing villages with and  
 308 without presence of VL-HIV or PKDL cases in the same or the previous year. The reported p-  
 309 value was calculated using Kruskal Wallis chi square test (non-normal distribution).

	Mean VL incidence/10,000/year on village level		
	present (SD)	absent (SD)	p-value $\chi^2$
<b>HIV-VL in the same year</b>	2.32 (5.70)	0.58 (2.77)	0.0001
<b>PKDL in the same year</b>	4.98 (9.98)	0.53 (2.54)	0.0001
<b>HIV-VL in the previous year</b>	1.70 (4.70)	0.68 (3.10)	0.0001
<b>PKDL in the previous year</b>	2.67 (5.68)	0.67 (3.07)	0.0001

310  
 311 **Table 2** : Results of bivariate (crude) and multivariate (adjusted) analysis using negative  
 312 binomial regression. Incidence rate ratios (IRR) for VL are presented, including 95% confidence  
 313 intervals (95% CI) and p-values. Statistically significant associations (p-values <0.05) are  
 314 highlighted in bold.

315  
 316

		Crude			Adjusted		
		IRR	95% CI	P-value	IRR	95% CI	P-value
Presence of VL-HIV in the same village in the same year	No	Ref.			Ref.		
	Yes	<b>4.07</b>	<b>(2.94 – 5.63)</b>	<b>&lt;0.001</b>	<b>2.16</b>	<b>(1.81 – 2.58)</b>	<b>&lt;0.001</b>
Presence of PKDL in the same village in the previous year	No	Ref.			Ref.		
	Yes	<b>4.63</b>	<b>(3.30 – 6.49)</b>	<b>&lt;0.001</b>	<b>2.37</b>	<b>(2.01 – 2.81)</b>	<b>&lt;0.001</b>
Interaction term VL-HIV(same year)*PKDL(previous year)		NA					0.795

year)


317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359



## REFERENCES

1. Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme. *PLoS neglected tropical diseases*. 2017;11(11):e0005877.
2. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. *Lancet Infect Dis*. 2003;3(2):87-98.
3. Ramesh V, Kaushal H, Mishra AK, Singh R, Salotra P. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study. *BMC Public Health*. 2015;15:1092.
4. Das AK, Harries AD, Hinderaker SG, Zachariah R, Ahmed B, Shah GN, et al. Active and passive case detection strategies for the control of leishmaniasis in Bangladesh. *Public Health Action*. 2014;4(1):15-21.
5. Garapati P, Pal B, Siddiqui NA, Bimal S, Das P, Murti K, et al. Knowledge, stigma, health seeking behaviour and its determinants among patients with post kalaazar dermal leishmaniasis, Bihar, India. *PloS one*. 2018;13(9):e0203407.
6. Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? *Bull World Health Organ*. 1992;70(3):341-6.
7. Mathur P, Samantaray JC, Vajpayee M, Samanta P. Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics. *J Med Microbiol*. 2006;55(Pt 7):919-22.
8. Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, Mitra G, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;59(4):552-5.
9. Directorate National Vector Borne Disease Control Programme India. Accelerated plan for Kala-azar elimination 2017 [Available from: <https://nvbdcp.gov.in/WriteReadData/1892s/Accelerated-Plan-Kala-azar1-Feb2017.pdf>] (accessed May 10, 2020).
10. Akuffo H, Costa C, van Griensven J, Burza S, Moreno J, Herrero M. New insights into leishmaniasis in the immunosuppressed. *PLoS neglected tropical diseases*. 2018;12(5):e0006375.
11. Molina R, Gradoni L, Alvar J. HIV and the transmission of *Leishmania*. *Annals of tropical medicine and parasitology*. 2003;97 Suppl 1:29-45.
12. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. *Clinical microbiology reviews*. 2008;21(2):334-59.
13. Tremblay M, Olivier M, Bernier R. *Leishmania* and the pathogenesis of HIV infection. *Parasitology today (Personal ed)*. 1996;12(7):257-61.
14. Mock DJ, Hollenbaugh JA, Daddacha W, Overstreet MG, Lazarski CA, Fowell DJ, et al. *Leishmania* induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. *PLoS pathogens*. 2012;8(4):e1002635.

- 360 15. Lopez-Velez RP-MJAGABFVJELBCP-CFAJ. Clinicoepidemiologic characteristics,  
361 prognostic factors, and survival analysis of patients coinfectd with human immunodeficiency  
362 virus and leishmania in an area of Madrid, Spain. 1998.
- 363 16. World Health Organization. Leishmaniasis and HIV coinfection [Available from:  
364 [https://www.who.int/leishmaniasis/burden/hiv\\_coinfection/burden\\_hiv\\_coinfection/en/](https://www.who.int/leishmaniasis/burden/hiv_coinfection/burden_hiv_coinfection/en/)  
365 (accessed April 7, 2020).
- 366 17. Singh S. Changing trends in the epidemiology, clinical presentation, and diagnosis of  
367 Leishmania-HIV co-infection in India. *International journal of infectious diseases : IJID : official*  
368 *publication of the International Society for Infectious Diseases.* 2014;29:103-12.
- 369 18. Cota GF, de Sousa MR, Rabello A. Predictors of Visceral Leishmaniasis Relapse in HIV-  
370 Infected Patients: A Systematic Review. *PLoS neglected tropical diseases.* 2011;5(6):e1153.
- 371 19. Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, et al. Visceral  
372 Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment  
373 Outcomes with Liposomal Amphotericin B (AmBisome). *PLoS neglected tropical diseases.*  
374 2014;8(8):e3053.
- 375 20. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in  
376 immunosuppressed individuals. *Clinical microbiology and infection : the official publication of*  
377 *the European Society of Clinical Microbiology and Infectious Diseases.* 2014;20(4):286-99.
- 378 21. The World Bank. Bihar Poverty, Growth and Inequality. 2016 [Available from:  
379 [http://documents.worldbank.org/curated/en/781181467989480762/pdf/105842-BRI-P157572-](http://documents.worldbank.org/curated/en/781181467989480762/pdf/105842-BRI-P157572-PUBLIC-Bihar-Proverty.pdf)  
380 [PUBLIC-Bihar-Proverty.pdf](http://documents.worldbank.org/curated/en/781181467989480762/pdf/105842-BRI-P157572-PUBLIC-Bihar-Proverty.pdf)] (accessed May 20, 2020).
- 381 22. National Vector Borne Disease Control Programme I. National Vector Borne Disease  
382 Control Programme, India. Kala-azar Cases and Deaths in the country since 2013. [Available  
383 from: <https://nybdcp.gov.in/index4.php?lang=1&level=0&linkid=467&lid=3750>] (accessed  
384 March 23, 2020).
- 385 23. National AIDS Control Organization, India. India HIV estimations 2017 - fact sheets  
386 [Available from:  
387 [http://naco.gov.in/sites/default/files/HIV%20Estimations%202017%20Report\\_1.pdf](http://naco.gov.in/sites/default/files/HIV%20Estimations%202017%20Report_1.pdf)] (accessed  
388 April 5, 2020).
- 389 24. Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et al. Quantifying the  
390 Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies. *Clinical infectious*  
391 *diseases : an official publication of the Infectious Diseases Society of America.* 2019;69(2):251-  
392 8.
- 393 25. Molina R, Lohse JM, Pulido F, Laguna F, López-Vélez R, Alvar J. Infection of sand flies  
394 by humans coinfectd with *Leishmania infantum* and human immunodeficiency virus. *The*  
395 *American journal of tropical medicine and hygiene.* 1999;60(1):51-3.
- 396 26. Ferreira GR, Castelo Branco Ribeiro JC, Meneses Filho A, de Jesus Cardoso Farias  
397 Pereira T, Parente DM, Pereira HF, et al. Human Competence to Transmit *Leishmania infantum*  
398 to *Lutzomyia longipalpis* and the Influence of Human Immunodeficiency Virus Infection. *The*  
399 *American journal of tropical medicine and hygiene.* 2018;98(1):126-33.
- 400 27. Das VN, Pandey RN, Siddiqui NA, Chapman LA, Kumar V, Pandey K, et al.  
401 Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic  
402 Infections and PKDL in Highly Endemic Villages in Bihar, India. *PLoS neglected tropical*  
403 *diseases.* 2016;10(12):e0005196.
- 404 28. Le Rutte EA, Zijlstra EE, de Vlas SJ. Post-Kala-Azar Dermal Leishmaniasis as a  
405 Reservoir for Visceral Leishmaniasis Transmission. *Trends in parasitology.* 2019;35(8):590-2.

- 406 29. Pijpers J, den Boer ML, Essink DR, Ritmeijer K. The safety and efficacy of miltefosine  
407 in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and  
408 meta-analysis. PLoS neglected tropical diseases. 2019;13(2):e0007173.
- 409 30. Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-leishmania therapy in  
410 visceral leishmaniasis among HIV infected patients: a systematic review with indirect  
411 comparison. PLoS neglected tropical diseases. 2013;7(5):e2195.  
412





### Incidence Rate Ratio

4 3 2 1 0 1 2 3 4

District

Darbhanga

3.43

2.41

Muzaffarpur

2.50

2.45

Samastipur

2.43

1.79

Saran

2.03

1.62

Siwan

1.57

2.72

Vaishali

2.91

1.69

IRR VL-HIV

IRR PKDL

